CollPlant Biotechnologies Ltd. (CLGN) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2021
Loading P/E history...
CLGN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, CollPlant Biotechnologies Ltd. (CLGN) trades at a price-to-earnings ratio of -0.3x, with a stock price of $0.39 and trailing twelve-month earnings per share of $-0.96.
The current P/E is 100% below its 5-year average of 73.0x. Over the past five years, CLGN's P/E has ranged from a low of 53.8x to a high of 92.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, CLGN trades at a 101% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CLGN trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CLGN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CLGN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 147.0 | - | +287%Best | |
| $8B | 25.5 | 1.11Best | -25% | |
| $3B | 30.4 | 6.91 | -15% | |
| $548M | 11.5Lowest | - | +14% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CLGN Historical P/E Data (2021–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $21.21 | $0.23 | 92.2x | +26% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $13.44 | $0.25 | 53.8x | -26% |
Average P/E for displayed period: 73.0x
See CLGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCLGN — Frequently Asked Questions
Quick answers to the most common questions about buying CLGN stock.
Is CLGN stock overvalued or undervalued?
CLGN trades at -0.3x P/E, below its 5-year average of 73.0x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CLGN's valuation compare to peers?
CollPlant Biotechnologies Ltd. P/E of -0.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CLGN's PEG ratio?
CLGN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2021.